Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
12/2007
12/27/2007US20070299048 Combination of Gaboxadol and 5Ht2 Antagonists
12/27/2007US20070299047 Combination of Organic Compounds
12/27/2007US20070299035 Use of chemical chelators as reversal agents for drug-induced neuromuscular block
12/27/2007US20070299031 Therapeutic agent for tumor of neural origin
12/27/2007US20070299019 Macrolides and methods for producing same
12/27/2007US20070299008 Transport Protein Which Is Used To Introduce Chemical Compounds Into Nerve Cells
12/27/2007US20070298999 Method for treating pain with a calmodulin inhibitor
12/27/2007US20070298998 Biomarkers for amyotrophic lateral sclerosis and methods using the same
12/27/2007US20070298129 Compounds and compositions for treating neuronal death or neurological dysfunction
12/27/2007US20070298124 ammonium trichloro(dioxyethylene-O,O')tellurate; epilepsy, inflammatory bowel disease, Crohn's disease and ulcerative colits
12/27/2007US20070298107 Pharmaceutical Compositions of Mirtazapine
12/27/2007US20070298106 Sustained Release Formulation Containing Selective Serotonin Reuptake Inhibitor and Method for the Preparation Thereof
12/27/2007US20070298099 Liquid and Semi-Solid Pharmaceutical Formulations for Oral Administration of a Substituted Amide
12/27/2007US20070298098 Controlled Release Compositions Comprising Levetiracetam
12/27/2007US20070298096 Analgesic/Antipyretic Compositions for Enhanced Absorption
12/27/2007US20070298090 Intraoral delivery of nicotine for smoking cessation
12/27/2007US20070298070 Nerve regeneration employing keratin biomaterials
12/27/2007US20070298057 Composition and method for modulating addictive behaviors
12/27/2007US20070298039 Immunoglobulin specific to receptor protein DR5 for treatment of cancer, inflammatory or autoimmune diseases
12/27/2007US20070298037 administering antagonist to ztnfr14 comprising antibodies, antibody fragments, proteins or polypeptides, for the treatment of psoriasis, inflammatory bowel disease or multiple sclerosis in mammals
12/27/2007US20070298029 Treatment of Neurodegenerative Diseases by the Use of Degs Inhibitors
12/27/2007US20070298028 Diagnostics and Therapeutics for Diseases Associated With Kallikrein 3 (Klk3)
12/27/2007US20070298027 Novel Target for Antiderpressant Therapy
12/27/2007US20070298020 Apoptotic entities for use in treatment of endothelium dysfunction disorders
12/27/2007US20070298016 Methods For The Generation Of Hepatocyte-Like Cells From Human Blastocyst-Derived Stem (Hbs)
12/27/2007US20070298009 protect neural cells from degeneration and/or death in response to traumatic brain injury or autoimmune disorders of the brain, such as multiple sclerosis and in reducing seizures; hypoxia/ischemia, toxic injury, and chronic neurodegenerative disorders including Parkinson's disease
12/27/2007DE202006017020U9 Verwendung von Kalium-, Magnesium-, Calcium- und Zink-Elektrolyten zur Behandlung des Elementemangel- und Austrocknungssyndroms Alzheimer und anderer Demenzen Use of potassium, magnesium, calcium and zinc electrolyte for the treatment of Alzheimer syndrome Elementemangel- and dehydration and other dementias
12/27/2007DE102006029573A1 Neue Quinazoline als Kinase-Inhibitoren New quinazolines as kinase inhibitors
12/27/2007DE102006029445A1 Neue 3-Cyano-chinoline als Kinase-Inhibitoren New 3-cyano-quinolines as kinase inhibitors
12/27/2007CA2658959A1 Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity
12/27/2007CA2656698A1 Cannabinoids for use in the treatment of neuropathic pain
12/27/2007CA2656625A1 Substituted isoindoles as bace inhibitors and their use
12/27/2007CA2656370A1 Quinazoline derivatives, their preparation, their use as tyrosine kinase inhibitors and medicaments comprising them
12/27/2007CA2656035A1 Crystalline duloxetine hydrochloride
12/27/2007CA2656034A1 Fused [d]pyridazin-7-ones
12/27/2007CA2655962A1 Crystalline duloxetine hydrochloride
12/27/2007CA2655759A1 Compositions and kits comprising a melatonin component and a chondroprotective component
12/27/2007CA2655654A1 New carbonylated (aza)cyclohexanes as dopamine d3 receptor ligands
12/27/2007CA2655604A1 Cyclopropyl amine derivatives
12/27/2007CA2655573A1 Therapeutic or prophylactic agent for multiple sclerosis
12/27/2007CA2655524A1 Arylsulfonamidyl tetralin derivatives and uses thereof
12/27/2007CA2655399A1 Pyrrolidine derivatives having activity at the glyt1 transporter
12/27/2007CA2655084A1 Novel heteroaryl substituted benzoxazoles
12/27/2007CA2655014A1 Cycloalkanopyrrolocarbazole derivatives and the use thereof as parp, vegfr2 and mlk3 inhibitors
12/27/2007CA2654822A1 Arylsulfonyl naphthalene derivatives and uses thereof
12/27/2007CA2654781A1 2-pyrazinecarboxamide derivatives
12/27/2007CA2654464A1 Compositions and kits comprising a melatonin component and a flavanol component
12/27/2007CA2654459A1 Compositions and kits comprising a melatonin component and an omega-3-fatty acid component
12/27/2007CA2653758A1 Tetralin and indane derivatives and uses thereof
12/27/2007CA2653355A1 Substituted phenyl methanone derivatives
12/26/2007EP1870419A2 Modulators of beta-amyloid peptide aggregation comprising d-amino acids
12/26/2007EP1870413A1 Antipruritic agent for pruritus caused by multiple sclerosis
12/26/2007EP1870405A1 Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands
12/26/2007EP1870402A1 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as VLA-4 inhibitors
12/26/2007EP1870107A1 Use of inducer of promyelocytic leukemia protein (PML) for treating polyglutamine expansion neurodegenerative diseases
12/26/2007EP1870106A2 Combination of egf/ghrp-6 for neuroregeneration of central nervous system
12/26/2007EP1870103A2 Use of uridine in combination with choline for the treatment of memory disorders
12/26/2007EP1870099A1 Protective agent for retinal neuronal cell comprising indazole derivative as active ingredient
12/26/2007EP1870098A2 Combined use of valsartan and calcium channel blockers for therapeutic purposes
12/26/2007EP1870097A1 Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
12/26/2007EP1870095A1 Composition for increasing anti-oxidation activity in blood
12/26/2007EP1869056A1 Novel 5-substituted 7-amino-ý1,3¨thiazoloý4,5-d¨pyrimidine derivatives
12/26/2007EP1869055A1 Novel 5,7-disubstituted ý1,3¨thiazoloý4,5-d¨pyrimidin-2(3h)-one derivatives
12/26/2007EP1869050A1 Novel substituted diazabicyclo derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
12/26/2007EP1869049A1 Imidazopyridazine compounds
12/26/2007EP1869039A2 Process for preparing bicyclic compounds
12/26/2007EP1869038A1 Substituted 5,6,7,8-tetrahydro-imidazoý1,2-a¨pyridin-2-ylamine compounds and their use for producing drugs
12/26/2007EP1869033A1 Novel enantiomers and their use as monoamine neurotransmitter re-uptake inhibitors
12/26/2007EP1869019A1 Bicyclic [3.1.0] heteroaryl amides as type i glycine transport inhibitors
12/26/2007EP1869018A1 3-triazolylthioalkyl-3-azabicyclo (3 - 1 - o) hexanes and their use as dopamine d3 receptor ligands
12/26/2007EP1869017A1 3- (1,2,4-triazol-3ylalkyl) azabriclo (3.1.0) hexane derivatives as modulators of dopamine d3 receptors
12/26/2007EP1869002A1 Substituted indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds, their preparation and use in medicaments
12/26/2007EP1869000A1 Cyclopentapyridine and tetrahydroquinoline derivatives
12/26/2007EP1868999A1 Pyridine-3-carboxamide derivatives as cb1 inverse agonists
12/26/2007EP1868994A1 Sulfonylpyrroles as histone deacetylase inhibitors
12/26/2007EP1868989A2 Inhibitors of neurotrypsin and determination thereof
12/26/2007EP1868643A1 Human antibodies with beta-amyloid peptide-binding capacity and their applications
12/26/2007EP1868626A1 Improved method for preparing ginkgo extracts having a reduced content of polycyclic aromatic hydrocarbons
12/26/2007EP1868625A1 Improved method for preparing ginkgo extracts having a low content of 4'-o-methyl pyridoxine and/or biflavones
12/26/2007EP1868614A2 Dosage regimen for the treatment of a traumatic brain injury with progesterone
12/26/2007EP1868602A1 Pharmacological treatment for sleep apnea
12/26/2007EP1868600A1 Spirocyclic cyclohexane derivatives for use in the treatment of substance dependency
12/26/2007EP1868597A1 Therapeutic use of nefopam and analogues thereof
12/26/2007EP1868568A1 Method for preparing a ginkgo extract having a reduced content of 4'-o-methyl pyridoxine and/or biflavones
12/26/2007EP1868432A2 Methods for treating anxiety related disorders
12/26/2007EP1751138B1 Indol-2-one derivatives for the treatment of central nervous disorders, gastrointestinal disorders and cardiovascular disorders
12/26/2007EP1711465B1 Hydroisoindoline tachykinin receptor antagonists
12/26/2007EP1525193B1 Acylaminothiazole derivatives, preparation and therapeutic use thereof
12/26/2007EP1491531B1 (1-indanone)-(1,2,3,6-tetrahydropyridine) derivative
12/26/2007EP1409518B1 Use of fragments of oxytocin for the preparation of a pharmaceutical composition in order to create eustasis
12/26/2007EP1233769B1 Imidazole derivatives
12/26/2007EP0817621B2 Pharmaceutical composition for transdermic delivery
12/26/2007CN101094854A Constrained compounds as cgrp-receptor antagonists
12/26/2007CN101094852A Substituted indolizines and derivatives as cns agents
12/26/2007CN101094687A Nutritional composition comprising indigestible oligosaccharides
12/26/2007CN101094675A Formulations of [1,4]diazepino[6,7,1-ij]quinoline derivatives
12/26/2007CN101094674A Use of n-desmethylclozapine to treat human neuropsychiatric disease
12/26/2007CN101094668A Use of selected compounds for protection of neurones and oligodendrocytes in the treatment of multiple sclerosis
12/26/2007CN101094665A Use of certain phenyl napthyl compounds for protection of neurons and oligodendrocytes in the treatment of multiple sclerosis (ms)
12/26/2007CN101094664A Use of certain phenyl-naphthyl compounds that do not have significant affinity to er alpha or er beta for protection of neurons and oligodendrocytes in the treatment of multiple sclerosis
1 ... 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 ... 1833